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Abstract 
Mutation profiling in colorectal cancer patients with microsatellite instability; High 
frequency of BRCA2 and EGFR somatic mutations 
Safoora Deihimi 
Advisor: Wafik S. El-Deiry 
 
Microsatellite instability (MSI) is a hallmark of deficient mismatch repair (MMR) and 
contributes to ~15% of colorectal cancer (CRCs). MSI can lead to mutations in proteins 
involved in double-strand break repair including BRCA2 and may involve drivers such as 
EGFR.  We analyzed 26 MSI-High (MSI-H) and 558 non-MSI-H CRCs that were profiled 
at Caris Life Sciences. The MSI-H CRCs had a significantly high mutation rate (50%) in 
BRCA2. We hypothesized there may be specifically enriched BRCA2 mutations in MSI-
H CRCs targeting the coding microsatellites in BRCA2 due to MMR deficiency. We 
investigated functional mutation patterns in BRCA2 in both MSI-H and non-MSI-H CRCs 
in a second cohort. Of 1104 profiled CRCs in the COSMIC v73 database, somatic BRCA2 
mutations were mapped for 101 MSI-H versus 916 non-MSI-H CRCs. MSI-H CRCs 
showed a significantly higher mutation rate in BRCA2 as compared to non-MSI-H (38% 
vs 6%, P<0.0000001) with enrichment in coding microsatellites. EGFR was mutated in 
45.5% of MSI-H and 6.5% of non-MSI-H tumors (P<0.0000001). Approximately 15-20% 
of the EGFR mutations found may be actionable through TKI therapy, including the 
N700D, L747*, G719D, T790M, and E884K EGFR mutants. BRCA2 mutations in MSI-
H CRCs included 75 unique novel mutations not known as somatic mutations in either 
breast cancer or pancreatic cancer per COSMIC v73. The BIC database 
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(http://research.nhgri.nih.gov/bic/) identified 5 BRCA2 deleterious mutations that have 
been reported as germ-line mutations in breast cancer. Five predictors and available 3-D 
structural information were used to predict deleterious properties of BRCA2 mutations 
including disruption of interactions with partner proteins DSS1 and RAD51. Some CRCs 
harbored multiple BRCA2 mutations. Therapeutic targeting of BRCA2 or EGFR mutations 
may be further explored in MSI-H CRCs.   
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INTRODUCTION 
Colorectal cancer (CRC) incidence and mortality rates are remarkably high 
worldwide, with 1.4 million new cases and approximately 700,000 deaths per year (1). 
With the rapid increase, the global incidence and mortality rate of CRC is predicted to 
undergo a 60% rise by 2030 (2). CRCs arise through genetic changes that impact various 
driver genes and in some tumors increased mutation rate occurs in microsatellite unstable 
tumors (3, 4). The hypermutable phenotype associated with microsatellite instability (MSI) 
results from loss of the mismatch repair (MMR) activity (5, 6). MSI is detected in a small 
fraction (<15%) of all CRCs, and such tumors have a better prognosis and different 
chemotherapeutic sensitivities as compared to non-MSI tumors (3, 5, 7, 8).  
 
Approximately 90% of hereditary non-polyposis colorectal cancer (HPNCC) 
patients are reported to be associated with germ-line mutations in MLH1 and MSH2 (3, 9). 
Germ-line, somatic and epigenetic inactivation of the MMR genes MLH1 and MSH2 
results in complete loss of MMR leading to oncogenesis, recognized as an MSI-H state 
both sporadically and in HPNCC (3, 10). A distinct MSI phenotype with a low level of the 
MMR markers MSH3, MSH6, PMS1 and PMS2 is known as the MSI-Low (MSI-L) CRC 
subtype with a weak effect on MMR system failure (3, 5, 6). The MMR pathway is believed 
not only to function as one of the most essential systems for maintenance of genome 
integrity, but also is to mediate DNA double-strand break (DSB) repair (10). Various 
studies have suggested a modulator effect of MSH2 and MLH1 in homologous 
recombination (HR) (10, 11).  Delays in the recruitment of RAD51 and MRE11 to DNA 
damage sites, and failed repair of DNA DSBs mediated by gene conversion is observed in 
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MSH2-deficient colorectal cancer cells (10, 11). Ionizing radiation can induce a high 
frequency of mitotic recombination in MLH1-null cells (10, 12). How mechanistically 
MSH2 and MLH1 impact on DSB repair and HR factors remains to be fully understood 
(13). 
 
Repetitive DNA sequences are more prone to mutation in tumors with MMR 
deficiency (7). Coding microsatellites in HR factors hRAD50 and MRE11A can be mutated 
in MSI tumors and are reported to sensitize MSI tumors to PARP-1 inhibitors (7). 
Repetitive sequences within the Bax or TGF-beta Type II receptor genes have been 
reported to be mutated in MMR-deficient CRCs (14). The BRCA2 protein is a fundamental 
element of HR and somatic mutations in BRCA2 are known cancer drivers (15, 16). There 
is little evidence to suggest that BRCA2 is associated with increased risk of colon cancer 
although it is known that BRCA1 carriers have about a 3-fold increased risk of CRC (17, 
18). The high frequency of repetitive sequences in BRCA2 could allow for frequent 
mutations in MSI tumors (19). Identification of somatic mutations in BRCA2 could provide 
a basis for therapy with PARP-1 inhibitors especially if the defects are biallelic (20). We 
hypothesized that BRCA2 harboring high frequency of microsatellites may be a substrate 
for mutation and may lead to a driver phenotype in tumors that have lost their MMR system 
and there is potential to acquire biallelic hits in BRCA2. 
 
Epidermal growth factor receptor (EGFR), a member of ErbB family, is a 
transmembrane glycoprotein that forms a receptor tyrosine kinase (21, 22). EGFR over 
expression is associated with tumorigenesis and malignancy of many epithelial tumors 
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including MSI colon cancer through activation of downstream signaling pathways 
involving RAS-RAF-MAPK and PTEN-PI3K-AKT (22, 23). EGFR mutations in the 
tyrosine kinase domain occur in ~10% of Non-small cell lung cancer (NSCLC), sensitize 
the patients to tyrosine kinase inhibitors (TKI) (24). These patients are typically non-
smokers, female and of Asian descent. There are limited reports on the incidence rate of 
EGFR mutation in colorectal patients (22, 25). Here, we further analyzed the mutation 
signature of EGFR for possible targeted therapy. 
 
MATERIAL AND METHODS 
Bioinformatics workflow. 
We downloaded the full Cosmic whole-genome data V73 and TCGA [COAD] selected 
mutations occurring in the large intestine, and did some filtering & subsequent annotation.  
Tissue-specific genes are picked and gene expression levels were confirmed with the 
TIGER (Tissue-specific Gene Expression and Regulation) database.  
Breast Cancer Information Core (BIC), an Open Access On-Line Breast Cancer Mutation 
Data Base, was applied to detect the previous identified BRCA2 mutations. 
 
Statistical analysis. 
Categorical variables were compared by χ2 test or Fisher exact test. All statistical tests 
were 2-sided. Statistical significance was defined as P < 0.01. 
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Functional prediction modeling.  
We used five predictors to predict BRCA2 mutations, including PolyPhen-2 
(Polymorphism Phenotyping v2) (26), SIFT (Sorting Intolerant From Tolerant) (27),  
PROVEAN (Protein Variation Effect Analyzer) (28), MutPred (29), and a predictor using 
support vector machine (SVM) developed by Qiong et al (30). These methods are trained 
on existing sets of mutation/phenotype association data and use sequence information from 
homologues, structure information, such as accessible surface area, and changes in amino 
acid properties to provide feature information as input to machine learning methods for 
phenotype prediction. PolyPhen-2 provides the probability of being deleterious.  If the 
probability is less than 0.5, the mutation is considered to be “benign”, otherwise, it is 
considered as “probably damaging”. SIFT outputs a normalized probability for each amino 
acid type, and a value of less than 0.05 is considered deleterious. PROVEAN uses an 
alignment-based score that measures the variation of a query sequence and its homolog 
before and after mutation.  The cutoff is -2.5 where PROVEAN has best specificity and 
sensitivity. A value of less than -2.5 is considered deleterious. MutPred provides 
probabilities of gain or loss of structure and function. We used 0.5 as cutoff, a value of less 
than 0.5 is considered deleterious. SVM predictor is based on support vector machine, used 
both sequence and structural information, trained on balanced data sets of deleterious and 
neutral mutations. SVM predictor also output probabilities. A value with >0.5 is considered 
as deleterious. We used BioAssemblyModeler (BAM) (31) software to do homology 
modeling, first backbone atoms are copied from template structure, then side-chains 
coordinates are built from with the program SCWRL4 (32). We used YASARA web site 
(33) [http://www.yasara.org/minimizationserver.htm] to perform energy minimization 
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using the YASARA force field. All structures are studied in PyMOL 
(https://www.pymol.org/). 
 
 
RESULTS 
Initial cohort of CRC analyzed by genomic profiling identifies frequent BRCA2 
mutations in MSI-H tumors. 
We analyzed the mutation data for 26 MSI-H and 558 non-MSI-H CRCs that were 
profiled at Caris Life Sciences. The MSI-H CRCs had significantly high mutation 
frequency in BRCA2 rather than non-MSI-H tumors (50% vs 14%, P<0.0001) (Fig.1). In 
the Caris cohort (Fig. 1), there was enrichment for BRCA2, BRCA1, and BRAF mutations 
in MSI-H CRCs while APC, KRAS, and p53 mutations were significantly reduced. A few 
other rarely mutated genes appeared to be significantly increased in MSI-H tumors in the 
Caris dataset including HNF1A, FBXW7, PTEN, CTNNB1, STK11, and SMO (Fig. 1). 
The specific deleterious BRCA2 mutations found in the Caris dataset in MSI-H CRCs are 
listed in Fig. 1. Among the frameshift BRCA2 mutations in MSI-H CRCs, 4 (50%) were 
found in repetitive sequences of the BRCA2 gene. 
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BRCA2 mutation list of MSI-H CRC patients in Caris database 
T3033fs 
(frame shift) 
W1692fs 
(frame shift) 
T3033fs 
(frame shift) 
K3327fs 
(frame shift) 
F12fs 
(frame shift) 
T3033fs 
(frame shift) 
I605fs 
(frame shift) 
P2639L 
(Damaging) 
L2890I 
(Damaging) 
M3217I L2155F D1911E C1290Y  
 
 
Figure 1. BRCA2 is highly mutated in MSI-H CRCs in an initial cohort of CRCs profiled by Caris 
Life Sciences. (A) Selected genes including deregulated genes in CRC in MSI-H and MSI Neg CRC 
subtypes is plotted. with different mutation frequencies among the MSI-H and non-MSI-H groups are 
shown. Fisher exact test was applied to compare the categorical variables. The p-value< 0.01 shows the 
significance of the comparison. (B) Damaging mutations including frameshift and missense mutations in 
MSI-H CRCs from Caris dataset are listed in the table. 
A 
C 
B 
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We further derived mutation data from the Catalog of Somatic Mutations in Cancer 
(COSMIC) database and The Cancer Genome Atlas (TCGA) data set (8, 34).  To profile 
and assess the potentially destructive mutations in BRCA2, we evaluated 101 MSI-H and 
916 MSS profiled samples with various prediction algorithms for their BRCA2 
functionally important somatic mutations (Table 1).  
 
Table 1. Molecular characteristics of defined cohorts from different databases. 
 MSI-H CRCs non-MSI-H (MSS) CRCs 
Caris Life 
Sciences 
Samples 26 558 
Mutations 
BRCA1 5 patients (Neutral) 28 Patients (Neutral) 
BRCA2 
13 patients (8/14 frameshift 
mutations) 
79 patients 
COSMIC 
(including 
TCGA 
data) 
Samples 101 916 
Mutations 
BRCA1 
28 patients (9/43 damaging 
mutations) 
45 patients (4/48 damaging 
mutations) 
BRCA2 
46 patients (48/75 damaging 
mutations) 
58 patients (25/58 damaging 
mutation) 
EGFR 
46 patients (32/75 damaging 
mutations targeting TK 
domain) 
60 patients (30/80 damaging 
mutations targeting TK 
domain) 
TP53 
68 patients (6/137 damaging 
mutations targeting hotspots) 
542 patients (194/606 
damaging mutations 
targeting hotspots) 
POLέ 43 patients (25 damaging) 39 patients (21 damaging) 
 
Somatic alterations within MLH1 and MSH2 proteins found in MSI-H patient 
tumors. 
The COSMIC v73 dataset has profiled patients with cancers including patients with 
cancer in their large intestine, displaying sequenced genes with mutations (35). The 
mutation collections for the large intestine in the present study were derived from COSMIC 
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whole genome version 73. Analyzing exome sequences, the COSMIC whole genome 
database profiled 1104 samples with CRCs for their somatic mutations in coding exons (8). 
Since microsatellite status (MS) is not available in COSMIC, we designed a cohort with 
bioinformatic tools to define the MS status regarding the potential loss of expression in 
MMR proteins. We defined coding variations with functional impact on corresponding 
protein as pathogenic or benign as predicted by the FATHMM online server 
(http://fathmm.biocompute.org.uk/). PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/) 
was applied to further verify damaging effect of missense mutations in MMR proteins.  
 
The MSI-H cohort was initially defined based on having damaging mutations in 
MLH1 and MSH2. CRCs containing either synonymous mutations or non-mutated MMR 
genes MLH1, MSH2, MSH3, MSH6, PMS1 and PMS2 signified the non-MSI-H cohort. 
Among the profiled CRC samples in COSMIC version 73, 101 MSI-H and 916 non-MSI-
H were classified according to our definitions. The MSI-L cohort with no clear connection 
with defective DNA MMR were excluded from our statistical analysis. Most of the 
mutations predicted to be pathogenic by FATHMM were also predicted to be damaging 
via the PolyPhen-2 algorithm, mapped on both MLH1 and MSH2 protein structures (Fig. 
2). MSI-H tumors had to have at least one of the somatic mutations with a damaging effect 
on MLH1 or MSH-2 that in some cases could be accompanied by other non-synonymous 
mutation(s) of MMR genes. The frequency of predicted MSI-H in the CRC population 
under study was observed at 17 percent (Supplementary Fig. 1), similar to the reported 
prevalence of MSI in CRC (7). As expected, CRC patients with MSI are detected more 
among stage II and less in stage IV (Supplementary Fig. 1) (7). Moreover, POLέ mutation 
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frequency was found to be significantly increased in MSI-H CRCs (42% vs. 4% in MSS, 
P<0.0000001) (Table1), as expected in hypermutable tumors (8).    
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Figure 2. MLH1 and MSH2 protein domains annotated with somatic non-synonymous alterations 
observed in MSI-H CRCs from the COSMIC database. (A) MLH1 domains and variants. Three known 
domains are shown in the protein structure. The alterations including missense, nonsense and frameshift 
mutations are mapped with respect to known domains. Different numbers and colors of triangles in the 
same positions are representatives of frequency and diversity of mutations in the same spot, respectively. 
Red triangles represent the truncated mutations, while missense variants are shown in blue, brown and 
green. Variants predicted by PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/) to be damaging are 
denoted in black-outlined triangle as well as red/orange rectangle. Red rectangles are representative of 
damaging mutations with high probability (>90%) and orange rectangles outline the mutations with 
possibility (>50%). (B) MSH2 domains and variants.  
 
BRCA2 is among the highly mutated genes in CRC patients with microsatellite 
instability. 
Microsatellite testing provides a predictive marker to identify the underlying MMR 
mutations and this may correlate with the mutation rate in the cell (9). We assessed the 
number of mutated genes in MSI-H and non-MSI-H tumors to determine whether MSI 
affects the number of mutated genes. A significantly higher rate of mutated genes in MSI-
H CRCs vs. non-MSI-H (boxplot median 526 vs 101; P<0.0000001) was found 
corresponding to non-functional MLH1 and MSH2 proteins (Fig. 3A). According to 
prediction-based non-MSI-H and MSI-H cohorts, we identified more (a 7.4-fold increase) 
somatic non-synonymous variations in MLH1 and MSH2 in MSI-H colorectal cancers than 
in non-MSI-H. A high number of mutated genes in some patients in the non-MSI-H group, 
shown in Fig. 3A could correspond to chromosomal instability (CIN) pathway as a distinct 
form of genomic instability promoting CRC (3, 4). Furthermore, enrichment of POLέ and 
EXO1 mutations were detected in 12/33 (36%) non-MSI-H patients with at least 1000 
mutations. Although POLέ mutations could lead to MMR deficiency, these mutations  may 
be late event promoting a hypermutable phenotype in CRC and do not necessarily 
demonstrate microsatellite instability (36). The Low number of mutations in patients with 
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less than 10 mutated genes in the non-MSI-H group can be either because of low-quality 
genome-wide exome sequencing to detect somatic mutations or being sequenced only for 
specific genes such APC, KRAS, and TP53 (Fig. 3A).  
 
Deregulation of RTK-RAS, WNT, PI3K, TGF-β and p53 signaling pathways in 
CRC has been reported in the Cancer Genome Atlas Network (TCGA) study (8).  To further 
identify MSI effects on mutation frequency of altered pathways in CRC, we compared non-
synonymous mutation frequency in the MSI-H versus non-MSI-H group. In this analysis, 
we identified APC, KRAS, NRAS and p53 are similarly mutated in both MSI-H and non-
MSI-H CRC samples: APC (88.11% vs. 71.39%), KRAS (42.57% vs. 39.62%), p53 
(62.37% vs. 58. 29%) and NRAS (8.92% vs. 5.78%; both fisher exact test) (Fig. 3B). 
 
Despite the significantly higher level of APC transcript in MSI-H, CRC subtypes 
are frequently mutated for APC with a non-significant difference (Fig. 3B, supplementary 
Fig. 3). Alterations in the p53 pathway were previously found in 59% of non-hypermutated 
cases, similar to our initial cohort (63%) and the latest cohort (67%) (8). However, our 
observation in new cohort is indicative of a non-significant difference in TP53 mutated 
cases among CRC subtypes (Fig. 3B). Both MSI-H and non-MSI-H group are shown to 
express the similar level of TP53 mRNA (Supplementary Fig. 3). Our mutation analysis 
displays non-MSI-H patients having a higher frequency of damaging mutations in p53 
hotspots (37) at 32% including p.R248, p.G245, p.G244, p.C238, p.M237, p.S215, p.R213, 
p.Y205, p.R196, p.I195, p.L194, and p.R175H, compared to MSI-H patients at 4% . The 
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data highlights the correlation of P53 mutation and advanced stage of colorectal cancer and 
reverse association with MSI (38).  
 
Significant enrichment of mutations in cancer-related genes involved in PI3K and 
TGFβ signaling pathways as well as BRCA genes is observed in MSI-H tumors (Fig. 3B). 
Considering the fact that these genes have the same level of transcript expression in both 
cohorts reflects high correlation of the mutated PI3K, TGFβ and BRCA genes with MSI 
CRCs. CRC patients with BRCA2 mutations are significantly more common in MSI-H 
than non-MSI-H cohort (37.6% vs 6.3%, p<0.0000001), and the same trend for BRCA1 
mutations (27.7% vs 4.9%, p<0.0000001) (Fig. 3B). Although KRAS and NRAS are 
mutated with high frequency in both MSI-H and non-MSI-H groups, BRAF corresponding 
to RTK-RAS pathways is more altered in MSI-H than non-MSI-H CRCs (32.67% vs 
13.10%; p=0.001) (Fig. 3B), consistent with the known association between MSI-H CRCs 
with BRAF mutations (8, 39).  
 
In comparison, we could not detect a significant difference in randomly picked 
housekeeping genes in both MSI-H and non-MSI-H cohorts (supplementary Fig. 2). Brain-
specific genes are less frequently mutated in both groups compared to the highly mutated 
list of genes. However, some brain-specific genes such as NGR3 and HAPLN2 are highly 
mutated in the MSI-H group, due to the underlying deficient MMR system (Supplementary 
Fig. 2). 
Diverse numbers of variations were observed in altered genes of individual CRC 
patients in each subtype. The Wilcoxon Rank Sum Test determined the distribution of the 
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number of mutations in each gene among MSI-H and non-MSI-H samples. The mean 
number of mutations in BRCA2 was determined to be significantly higher in the MSI-H 
than the non-MSI-H group (2.3 vs. 1.1, p<0.0001), suggesting that each CRC patient with 
MSI has higher number of BRCA2 mutations than patients in non-MSI-H subtype (Fig. 
3C). Nevertheless, BRCA1 and EGFR had the same mean number of alterations in both 
groups (Fig. 3C). Although CRC patients in both subtypes have similar mutation frequency 
of APC and TP53, MSI-H CRCs are observed to harbor more APC and TP53 mutations 
individually compared to patients in non-MSI-H cohort (Fig. 3C). 
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Figure 3. The BRCA2 gene is among the most highly mutated genes with a higher mean number of 
mutations per tumor in MSI-H CRCs. (A) Difference in number of mutated genes in CRC patients with 
MSI-H and MSS are plotted in boxplot. (B) Genes with different mutation frequencies among the MSI-H 
and MSS groups are shown with respect to matters of significance. (C) The columns represent the mean 
of the number of mutations in the gene, across both MSI-H and MSS samples. The distribution of mutation 
counts between MSI-H and MSS samples were compared by Wilcoxon test. Fisher exact test was applied 
to compare the categorical variables. The p-value< 0.01 shows the statistically significance of the 
comparison. 
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BRCA2 mutations are distinct between non-MSI-H versus MSI-H CRCs. 
We investigated BRCA1/2 mutations in both CRC patient sample groups to 
decipher the statistical, domain distributional, and functional difference in BRCA 
mutations of each group. Among 101 MSI-H group, 46 CRC patients had 88 (75 unique) 
somatic BRCA2 mutations including 9 frameshift/nonsense (truncating the protein), 56 
missense (dysfunctional protein), 9 silent mutations along with one mutation in the splicing 
site (Table 1, Supplementary Fig. 4). In contrast, only 58 CRC patients hold 65 (58 unique) 
somatic BRCA2 mutations among 916 non-MSI-H group.  
 
Somatic mutations in BRCA2 derived from COSMIC dataset v73 were mapped on 
the BRCA2 protein structure with known functional domains (Fig. 4). The majority of 
somatic mutations were missense variants with unknown functional effect. Using the 
protein structural predictor, PolyPhen-2, we assigned missense mutations as damaging or 
neutral. High score of Polyphen-2 is indicative of missense mutations prevention of partial 
or total misfolding of the corresponded domains in the protein. Of the 56 BRCA2 missense 
mutations detected in MSI-H, 39 (70%) were predicted to be damaging, disrupting protein 
structure and protein-protein interaction interference (Fig. 3, Table 2). We did not detect a 
significant difference in BRCA1 somatic mutations in the MSI-H vs non-MSI-H CRC 
groups (Table 1). Therefore, our study focused more on BRCA2 somatic mutations in MSI-
H CRCs. 
 
We show that MSI-H CRCs display a distinct pattern of BRCA2 mutations as 
reflected in the frequency, diversity and position of the mutations by comparison to the 
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non-MSI-H CRCs. Comparable damaging BRCA mutations among the mutations detected 
in MSI-H vs. non-MSI-H CRCs were predicted (64% vs 43%, p=0.0045) (Fig. 4). More 
frameshift and/or nonsense point mutations observed to be distributed in N-terminal, BRC 
repeats and C-terminal in the MSI-H group (Fig. 4). These could generate a truncated 
protein which may be subject to protease-mediated degradation and potentially lead to 
deficient HR in the cell. Most of the mutations accumulated in the C-terminal portion of 
BRCA2 suggesting this area may have an important function, through interaction with 
DSS1 and RAD51 to facilitate HR (40). Mutations in these C-terminal domains with high 
mutational density could be tumor-specific or due to environmental influence. Only few 
BRCA2 mutations in CRCs have been reported in breast/ovarian cancer suggesting that 
these mutations are CRC specific.    
 
Different repetitive sequences (mononucleotides, dinucleotides, and trinucleotides) 
and their frequency were sought in BRCA2 and they were integrated with corresponding 
somatic mutations and involved domains. Of 123 distinct BRCA alterations in both CRC 
groups, 39 variations with deleterious effect were mapped on coding microsatellites 
(Supplementary Table 1, Fig. 4B). Altogether, our data suggests coding microsatellites in 
BRCA2 are more mutated with higher potential for damaging mutations in the MSI-H 
patients than the non-MSI-H group. This analysis highlights the significance of the 
underlying genetic signature and potential impact of deficient MMR on mutations of 
coding microsatellites in BRCA2.  
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Functional prediction modeling reveals candidate damaging BRCA2 mutations. 
We sought to identify somatic mutations that may damage protein function. We 
used five different algorithms to predict BRCA2 mutations for their destructive effects on 
the encoded protein, including PolyPhen-2 (Polymorphism Phenotyping v2) (26), SIFT 
(Sorting Intolerant From Tolerant) (27), PROVEAN (Protein Variation Effect Analyzer) 
(28) , MutPred (29), and a predictor using support vector machine (SVM) developed by 
Qiong et al (30). We used the consensus result from five predictors. A mutation is predicted 
to be deleterious if at least three predictors designated it to be deleterious. Structural 
information was used to verify the predictions. Since there is no human BRCA2 structure 
containing our mutations available in the Protein Data Bank (PDB), we used a mouse 
BRCA2 structure PDB: 1MIU as our template to model human BRCA2. 1MIU is a 
complex structure consisting of a mouse BRCA2 chain (sequence [2378-3115]) and human 
DSS1 proteins (Fig. 5A).  
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Figure 5. Model depicting the mutations in human BRCA2 that may impact interaction with DSS1. 
(A) The structure contains 13 mutations which are colored in magenta and shown in sticks. The residues 
and their sequence numbers are labeled in black. The figure is generated by PyMOL 
(https://www.pymol.org/pymol). (B)  The hydrogen bonds of Arg2520 and Glu14 and Glu18 of DSS1. 
The hydrogen bond is colored in green and shown in dot lines. The residues are colored in elements, where 
oxygen atom is colored in red, nitrogen is colored in blue. A hydrophilic pocket of DSS1 is composed of 
all negative electrically charged residues Glu14, Glu15, Asp16, Asp17 and Glu18. (C) Thr3085 has no 
side-chain interactions with its neighbor residues (Lys3083, Lys3084, Gly3086 and Leu3087). 
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           Table 2 shows the consensus result from functional predictors and structural 
modeling. We further searched for common mutations of BRCA2 in breast and ovarian 
cancers in the Breast Cancer Information Core (BIC) (http://research.nhgri.nih.gov/bic/), 
and pancreatic and uterine cancer in COSMIC. Among all missense mutations of BRCA2 
in MSI-H CRCs, 9 were previously reported in breast, ovarian, pancreatic and uterine 
cancers and 14 variants hit the same reported spots in breast cancer but with different amino 
acid substitutions in CRC. Except for 3, the other 20 mutation hits with history of 
occurrence in different types of cancer including breast and ovarian have damaging effect 
on BRCA2 protein (Table 2). 
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Table 2. The consensus prediction results of BRCA2 mutations in MSI-H patients 
Mutation 
CDS 
Mutation 
AA 
Breast/ovarian 
/pancreatic/ 
uterine cancer 
germline 
mutations 
Consensus 
EXAC 
frequency 
Site 
subtype 
Microsatellite 
target 
c.10151G>A p.R3384Q BREAST Deleterious N/A rectum X 
c.1334C>A p.S445Y N Neutral N/A colon  
c.1368G>T p.E456D N Deleterious N/A rectum X 
c.1435G>T p.D479Y PANCREATIC Deleterious N/A colon  
c.1838T>G p.L613R N Deleterious <1/10,000 colon  
c.1922C>A p.S641Y N Deleterious N/A caecum  
c.2102T>G p.F701C N Deleterious N/A colon X 
c.2164A>C p.K722Q N Deleterious N/A rectum X 
c.2296G>A p.A766T N Neutral N/A colon  
c.2491G>A p.V831I BREAST Neutral N/A colon  
c.2495A>G p.E832G N Neutral N/A colon  
c.2632G>A p.D878N N Neutral <1/10,000 caecum X 
c.2701C>A p.L901I N Neutral N/A colon  
c.2851C>A p.L951I N Neutral N/A colon  
c.2867A>C p.K956T N Neutral N/A colon  
c.3050T>C p.I1017T 
SAME 
POSITION 
Deleterious N/A colon  
c.3141T>G p.I1047M N Deleterious N/A rectum  
c.3575T>G p.F1192C BREAST Deleterious 
1/10,000-
0.001 
colon  
c.4012G>A p.G1338S 
SAME 
POSITION 
Deleterious N/A caecum  
c.4012G>T p.G1338C 
SAME 
POSITION 
Deleterious N/A colon  
c.4054G>T p.D1352Y BREAST Deleterious N/A colon  
c.4144G>A p.E1382K 
SAME 
POSITION 
Deleterious N/A colon X 
c.4427A>G p.D1476G N Deleterious Singleton colon  
c.4778A>G p.E1593G N Deleterious N/A colon  
c.4790C>A p.S1597Y N Neutral N/A rectum X 
c.4913A>G p.K1638R OVARIAN Neutral N/A caecum  
c.4914A>T p.K1638N N Deleterious N/A caecum  
c.52C>T p.R18C N Deleterious N/A colon X 
c.561G>T p.E187D 
SAME 
POSITION 
Deleterious Singleton caecum  
c.5637G>T p.E1879D 
SAME 
POSITION 
Deleterious N/A rectum X 
c.6050A>C p.K2017T N Deleterious N/A rectum X 
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c.6473T>G p.F2158C N Neutral N/A caecum  
c.6652G>T p.D2218Y N Deleterious N/A rectum  
c.6728C>A p.S2243Y N Deleterious N/A rectum  
c.6743A>T p.H2248L N Neutral N/A NS  
c.7132T>G p.S2378A 
SAME 
POSITION 
Deleterious N/A rectum  
c.7243C>T p.H2415Y N Deleterious N/A colon X 
c.7244A>G p.H2415R N Neutral Singleton colon X 
c.7481G>A p.R2494Q BREAST Deleterious N/A rectum  
c.7559G>A p.R2520Q BREAST Deleterious <1/10,000 caecum  
c.7904A>G p.E2635G N Deleterious N/A colon  
c.8009C>T p.S2670L BREAST Deleterious N/A rectum  
c.8032A>G p.R2678G N Deleterious N/A colon  
c.8150C>T p.A2717V 
SAME 
POSITION 
Deleterious N/A colon  
c.8360G>T p.R2787L 
SAME 
POSITION 
Deleterious N/A caecum  
c.841G>T p.D281Y 
SAME 
POSITION 
Deleterious N/A colon  
c.8858A>C p.E2953A N Neutral N/A caecum  
c.8971C>T p.R2991C 
SAME 
POSITION 
Deleterious Singleton colon  
c.9047C>A p.S3016Y N Deleterious N/A rectum  
c.9253A>G p.T3085A 
SAME 
POSITION 
Neutral N/A caecum X 
c.9331G>A p.E3111K N Deleterious N/A colon  
c.9539T>G p.L3180R 
SAME 
POSITION 
Deleterious N/A rectum  
c.963A>C p.Q321H 
SAME 
POSITION 
Neutral N/A rectum X 
c.9956C>A p.S3319Y N Deleterious N/A colon X 
c.996T>G p.I332M N Neutral N/A caecum X 
c.9995C>A p.S3332Y N Deleterious N/A colon X 
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EGFR is highly mutated in MSI-H CRCs targeting the tyrosine kinase (TK) domain. 
Unlike the previous reports (25, 41), our mutation analysis revealed a significantly 
high EGFR mutation frequency in CRC MSI-H subtype (45.5% vs. 6.5% in non-MSI-H 
CRCs, p<0.0000001) (Fig. 3B). To find out the domain distribution and functional patterns 
of EGFR mutations in CRC, we mapped the damaging mutations including nonsense and 
(deleterious-predicted) missense mutations. Of 101 MSI-H CRCs, 46 patients had 75 
EGFR mutations including 2 nonsense (with deleterious effect), 53 missense mutations, 
and 20 silent mutations (Table 1). Somatic EGFR missense mutations derived from 
COSMIC database v73 were predicted by PolyPhen-2 and FATHMM for their 
deleterious/dysfunctional effects, mapped on the EGFR protein structure with respect to 
known domains (Fig. 6). Of 53 missense mutations, 34 (64%) were predicted to be 
damaging (31 with probability>99% & 4 with probability>50%) (Fig. 6, Table 1). A high 
frequency of EGFR mutations (82%) was observed in the TK domain, targeting exons 18-
24. These retain the extracellular domain with potential for targeted therapy by antibodies 
or small molecules targeting the TK domain (Fig. 6). EGFR protein expression can be 
regulated transcriptionally (42), however, our analysis was not indicative of significant 
difference of EGFR mRNA expression between the MSI-H and non-MSI-H group 
(Supplementary Fig. 3). The result suggests that overexpression correlating to colon cancer 
could be related to other expression regulations including translational modifications.  
  
26 
 
  F
ig
u
re
 6
. 
E
G
F
R
 p
ro
te
in
 d
o
m
a
in
 s
tr
u
ct
u
re
 a
n
n
o
ta
te
d
 w
it
h
 a
ct
iv
a
ti
n
g
 a
s 
w
el
l 
a
s 
p
o
te
n
ti
a
ll
y
 d
a
m
a
g
in
g
 s
o
m
a
ti
c 
a
lt
er
a
ti
o
n
s 
in
 M
S
I-
H
 v
s.
 M
S
S
 C
R
C
s.
 
F
u
n
ct
io
n
al
 d
o
m
ai
n
s 
ar
e 
an
n
o
ta
te
d
 i
n
 d
if
fe
re
n
t 
co
lo
re
d
-b
o
x
es
. 
T
ru
n
ca
ti
n
g
 v
ar
ia
n
ts
 i
n
cl
u
d
in
g
 n
o
n
se
n
se
 a
n
d
 f
ra
m
es
h
if
t 
m
u
ta
ti
o
n
s 
ar
e 
sh
o
w
n
 i
n
 r
ed
. 
M
is
se
n
se
 
m
u
ta
ti
o
n
s 
ar
e 
d
en
o
te
d
 i
n
 b
lu
e 
as
 w
el
l 
as
 b
ro
w
n
 i
n
 t
h
e 
sa
m
e 
sp
o
t.
 V
ar
ia
n
ts
 p
re
d
ic
te
d
 b
y
 P
o
ly
P
h
en
-2
 (
h
tt
p
:/
/g
en
et
ic
s.
b
w
h
.h
ar
v
ar
d
.e
d
u
/p
p
h
2
/)
 t
o
 b
e 
d
am
ag
in
g
 a
re
 
d
en
o
te
d
 i
n
 b
la
ck
-o
u
tl
in
ed
 t
ri
an
g
le
. 
O
ra
n
g
e 
re
ct
an
g
le
s 
o
u
tl
in
e 
th
e 
m
u
ta
ti
o
n
s 
w
it
h
 p
o
ss
ib
il
it
y
 (
>
5
0
%
).
  
   A
 
27 
 
DISCUSSION 
MSI caused by a deficient MMR system leads to the hypermutable phenotype that 
is detected in ~15% of all CRCs. Each cancer and its subtypes are characterized by a 
specific somatic mutation signature. Large-scale tumor sequencing studies have produced 
numerous correlations (43). However, distinguishing tumor “driver” mutations from 
“passenger” mutations can be a challenge. Functionally damaging mutations or cancer-
driving mutations are usually differentiated from neutral mutations based on their 
frequency despite the fact that they could occur at very low frequencies among tumors (15).  
 
The BRCA2 protein is a fundamental element of HR and somatic mutations in 
BRCA2 are known cancer drivers (15, 16). The high frequency of repetitive sequences in 
BRCA2 could allow for frequent mutations in MSI tumors (19). Our data show a distinct 
pattern and comparatively frequent BRCA2 mutations in MSI-H CRCs. Functionally 
damaging mutations predicted in BRCA2 may disrupt the protein-protein interactions (Fig. 
3A, Table 2). Homologous recombination is defective in cancer cells with mutant BRCA1 
or BRCA2 genes, leading to more genetic abnormalities. Our results represent the 
accumulation of relatively CRC-exclusive BRCA2 mutations in the C-terminal area where 
BRCA2 interacts with DSS1 and RAD51 to facilitate HR. Yet to be further studied, 
discriminating the environmental influence on somatic mutations as tumor-specific ones 
may be pursued. Dysfunctional or semi-functional BRCA2 can effect on drug sensitivity, 
especially if biallelic. Likewise, we show that mutations in the BRCT domains of BRCA2 
is another hotspot, contributing to partial functionality or even protease-mediated 
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degradation. It is clear based on present knowledge that tumors with biallelic loss of 
BRCA2 may be considered for therapeutic strategies that use PARP inhibitors. 
 
EGFR has an extracellular ligand-binding domain, a single membrane-spanning 
region, and a cytoplasmic tyrosine kinase domain. Activation of the EGFR by a ligand 
leads to phosphorylation of its cytoplasmic tails. EGFR activation stimulates complex 
intracellular signaling pathways such as RAS-RAF-MAPK and PTEN-PI3K-AKT 
pathways. A Korean group (44) previously reported a frequency of 22.4% of EGFR 
mutations targeting exon 18 in CRC patients in Korea. Our mutational analysis indicates a 
45.5% EGFR mutation frequency in CRC patients with MSI-H tumors. EGFR mutations 
detected in CRC mainly target the TK domain, covering exons 18-24, which have potential 
for therapeutic targeting by anti-EGFR antibodies or small molecule EGFR inhibitors. 
Although rare nonsense EGFR mutations leading to truncated protein were detected in 
CRCs, we predicted about 65% of EGFR missense mutations to be damaging by the 
available predictors (Fig. 6, Table 1).  
 
The interaction between proteins and background expression patterns can be 
utilized in pharmacological studies (45). Although we didn’t detect a different mRNA 
expression level of EGFR between CRC subtypes, EGFR is regulated in a different level. 
Furthermore, NSCLCs with EGFR mutations and relatively half of CRC patients without 
KRAS mutation benefit from anti-EGFR therapies. We detected 477 (43%) colorectal 
cancer patients profiled in COSMIC V73 to have KRAS mutations, reflecting that almost 
half of CRC patients are not responsive to anti-EGFR antibody therapies. Non-MSI-H 
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CRCs, in particular, were highly (80%) mutated in G12 and G13 positions such as G13V 
and G13D compared to 14 (26%) MSI CRCs. The data suggests that non-MSI-H patients 
are more likely to harbor KRAS mutations which makes them resistant to anti-EGFR 
antibodies such as Cetuximab and panitumumab.   
 
The lack of response to EGFR therapy may in part be related to BRAF mutations, 
which are significantly increased in MSI-H CRCs. EGFR inhibitors targeting tyrosine 
kinase (TKI) are not known to be effective drugs for CRC patients with KRAS mutation. 
Moreover, the T790M mutation in EGFR confers resistance to EGFR TKIs Gefitinib or 
Erlotinib (Fig. 6)(44). The EGFR T790M mutation may rarely occur as a primary resistance 
mutation together with a sensitizing mutation. Our data is indicative of the presence of a 
patient with T790M mutation before treatment profiled by COSMIC. There are now drugs 
that target the T790M mutation in EGFR. On the other hand, patients with N700D, L747*, 
and G719D have been reported to be sensitive to TKIs and may benefit from Gefitinib or 
Erlotinib. The EGFR E884K mutation confers sensitivity to Gefitinib, but resistance to 
Erlotinib (46). Characterizing the EGFR activating mutations via identifying 
authophosphorylation of EGFR via immunohistochemistry (IHC) can be done to establish 
which CRC patients with EGFR-mutated tumors may derive any benefit from EGFR-
targeted therapeutics. This may be worth further investigation for selected patients with 
metastatic disease who have no remaining therapeutic options. 
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Figure S1. 17% of CRCs, the predicted MSI cohort, has high frequency of stage II CRC. (A) Distribution of 
CRC subtypes are plotted in the Pie chart. MSI includes both MSI-H and MSI-L populations. (B) Distribution of CRC 
stages of both MSI and MSS groups in the cohort is plotted together.  
 
 
 
Figure S2. Low frequency of mutations is seen in either randomly picked housekeeping or brain-specific genes 
(47). (A,B) Genes with different mutation frequency in both MSI-H and MSS groups are shown with the matter of 
significance. Fisher exact test was applied to compare the categorical variables. The p-value< 0.01 shows the 
significance of the comparison. 
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Figure S3. Association between microsatellite instability and mRNA expression of NFKB1/2, ATM/ATR, CHEK1/2, 
SMAD4, EGFR, CD274, SPATA2, CTNNB1, AKT1, APC, KRAS, BRCA1/2, TP53, POLέ in CRC patients.  
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Figure S4. One of the BRCA2 alterations was detected in splicing site. The red marked site is outside of the coding 
zone, considered the splicing site. Graphic representation of the specific site visualized with Integrative Genomics 
Viewer (IGV) software. 
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Table S1. Polynucleotide repeats in coding BRCA2 are hotspots for alterations. 
 repeats counts Mutation involved Involved Domain 
M
o
n
o
n
u
cl
eo
ti
d
e
 
AAAA 
AAAAA 
AAAAAA 
AAAAAAA 
AAAAAAAA 
AAAAAAAAAA 
103 
60 
13 
8 
2 
1 
K2017T, T1629A 
Between BRC 7,  8 
Interaction with NPM1 
 
BRCA2DBD_OB3 
BRCA2DBD_OB2 
Q321H, K965T, K722Q,K3360fs*23 
 
N319fs*5 , T3085A 
T 3033fs*29 
TTTT 
TTTTT 
TTTTTT 
TTTTTTTT 
TTTTTTTTTT 
52 
16 
3 
1 
1 
I332M, H2415Y, H2415R, N337N, 
D1096N/E, F2349C, F2568C 
Y232C 
Interaction with FANCD2 
CCCC 
CCCCC 
12 
1 
  
GGGG 5   
D
in
u
cl
eo
ti
d
e
 
ACAC 15 
12 
R18C Interaction with PALB2 
ACACA 
CACA 
CACAC 
CACACA 
26 
2 
3 
  
TCTC 
TCTCT 
TCTCTC 
TCTCTCT 
TCTCTCTC 
19 
10 
4 
1 
1 
S3319Y 
S3332Y 
S1597Y 
 
L2155H 
Around NLS 
Around NLS 
Interaction with POLH 
CTCT 
CTCTC 
CTCTCT 
23 
1 
2 
D878N Interaction with NPM1 
AGAG 
AGAGA 
AGAGAG 
AGAGAGA 
29 
19 
3 
1 
 
 
E456D, E510* 
 
 
GAGA 
GAGAG 
GAGGAG 
26 
4 
2 
E1879D Between BRC 6, 7 
GTGT 
GTGTG 
GTGTGT 
13 
5 
1 
  
 TGTG 
TGTGT 
TGTGTG 
25 
10 
1 
  
ATAT 
ATATA 
ATATAT 
42 
11 
4 
 
N1435H 
H962H 
 
Interaction with NPM1 
TATA 
TATAT 
TATATA 
22 
7 
1 
S1961G 
Y2997* 
 
BRCA2DBD_OB2 
GCGC 1   
 
T
ri
n
u
c
le
o
ti
d
e 
 
AACAAC 
AACAACA 
AACAACAA 
2 
1 
1 
  
AAGAAG 
AAGAAGA 
AAGAAGAA 
3 
4 
3 
 
E1382K 
E2599* 
 
Interaction with POLH 
AATAAT 
AATAATA 
AATAATAA 
7 
2 
1 
N987delN Interaction with NPM1 
ACAACA 
ACAACAA 
3 
1 
  
ACGACG 
ACTACT 
1 
3 
R3384Q NLS 
AGAAGA 
AGAAGAA 
9 
4 
E2004E 
E49*  
 
Transcriptional activation  
AGCAGC 
AGCAGCA 
AGCAGCAG 
AGCAGCAGC 
1 
3 
1 
1 
  
AGGAGG 
AGGAGGA 
2 
2 
  
AGTAGT 1   
ATAATA 1   
ATTATT 
ATTATTA 
6 
1 
  
CAACAA 
CAACAAC 
5 
1 
  
 ATGATG 
ATGATGA 
1 
3 
  
ATCATC 3   
CACCAC 
CACCACC 
2 
1 
  
CAGCAGCA 1   
CATCAT 
CATCATC 
CATCATCA 
1 
1 
1 
  
CCACCA 
CCACCACCAC 
2 
1 
  
CGCG 1   
CTACTA 4   
CTCCTC 1 S3319Y Around NLS 
CTGCTG 
CTGCTGC 
1 
1 
  
CTTCTT 
CTTCTTC 
1 
2 
  
GAAGAA 
GAAGAAG 
GAAGAAGA 
GAAGAAGAA 
15 
1 
1 
1 
  
GATGAT 
GATGATG 
GATGATGA 
1 
1 
1 
  
GCAGCA 
GCAGCAG 
1 
1 
  
GGAGGA 
GGAGGAG 
2 
1 
  
GGTGGT 2   
GTAGTA 
GTAGTAG 
1 
1 
  
GTCGTC 1   
GTGGTG 2   
GTTGTT 2   
TAATAA 2 F701C Interaction with NPM1 
 TAATAAT 
TAATAATA 
1 
1 
TACTAC 
TACTACT 
2 
1 
  
TAGTAG 
TAGTAGT 
1 
1 
  
TATTAT 
TATTATT 
1 
1 
  
TCATCA 1   
TCCTCC 1   
TCTTCT 1   
TGATGA 
TGATGAT 
5 
1 
  
TGCTGC 1   
TGGTGG 2   
TGTTGT 
TGTTGTT 
1 
2 
  
TTATTA 3 F701C  Interaction with NPM1 
TTCTTC 
TTCTTCT 
7 
1 
 
 
 
TTGTTG 2   
 
*Red-colored mutations are predicted to be damaging. 
** The underlined mutations exist within the underlined domains. 
 
 
  
